Altimmune reports 48‑week Phase 2b trial shows liver and weight benefits of pemvidutide
Altimmune announced that its 48‑week IMPACT Phase 2b trial in patients with metabolic dysfunction‑associated steatohepatitis met multiple efficacy endpoints, including reductions in liver fat, inflammation and fibrosis and sustained weight loss. The study enrolled 212 biopsy‑confirmed participants who received weekly subcutaneous pemvidutide at 1.2 mg, 1.8 mg or placebo. About 1% of patients on pemvidutide stopped treatment because of adverse events, which were mostly mild to moderate. The company noted that pemvidutide holds FDA Fast Track and Breakthrough Therapy designations for MASH and that a Phase 3 trial began in July 2026.
Why it matters
The positive Phase 2b data may increase investor confidence in Altimmune’s pipeline and could drive demand for the stock ahead of the Phase 3 readout, according to the company’s press release.
Key facts
- 1The trial enrolled 212 participants with biopsy‑confirmed MASH and fibrosis stages F2 or F3. investing.com
- 2Participants were randomized to weekly subcutaneous pemvidutide doses of 1.2 mg, 1.8 mg or placebo. investing.com
- 3Approximately 1% of patients receiving pemvidutide discontinued treatment due to adverse events. investing.com
- 4Pemvidutide has FDA Fast Track designations for MASH and alcohol use disorder, and Breakthrough Therapy designation for MASH. investing.com
- 5Altimmune initiated the PERFORMA Phase 3 trial in MASH in July 2026. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.